Loading stock data…
SENS
$5.10-1.51 (-22.84%)
Market ClosedLast close May 1
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Senseonics Holdings, Inc. in the Healthcare sector is trading at $5.10. The stock is currently near its 52-week low of $4.96, remaining 33.4% below its 200-day moving average. Technical signals show oversold RSI of 28 and bearish MACD signal, explaining why SENS maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 28) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.10
Potential Upside
5%
Whystock Fair Value$5.35
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Buy
Mean target$18.92+270.9%
Range$9.00 – $31.00
Fundamentals
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$289.28M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.05
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
352.18%
Volume
Today's trading volume
6.34M
Recent News
Top Midday Decliners
BayFirst Financial's (BAFN) shares sank 28% after the company reported a wider Q1 loss and lower rev
Study Supports GlucoTrack’s Blood Glucose Monitoring Implant
By Karen Roman GlucoTrack, Inc. (Nasdaq: GCTK) said a peer-reviewed study published in the Institute of Electrical and Electronics Engineers Sensors Journal supported the feasibility of long-life implantable continuous glucose monitors like the devices the company develops. The article came out on April 7, 2026, and is the result of a partnership between GlucoTrack and […]
3 European Stocks Estimated To Be Trading At Discounts Of Up To 48.2%
As European markets rally following a U.S.-Iran ceasefire, the STOXX Europe 600 Index has seen a significant gain of 3.05%, with major indices in Germany, Italy, and France also posting strong performances. Amid this optimistic environment, identifying undervalued stocks can be particularly appealing as investors look for opportunities that may benefit from improved sentiment and potential market recovery.
Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets
Johnson & Johnson’s restated fourth-quarter holdings report, filed last week, reveals that the company exited three biotechs while retaining its stakes in several rumored acquisition targets. The changes included the sale of 247,598 shares in Arrowhead Pharmaceuticals previously a partner of Johnson & Johnson’s Janssen unit, which rebranded as its Innovative Medicine division. Johnson & Johnson also exited BiomX another former collaborator, through the sale of 96,866 shares.
Senseonics Reports Strong One-Year Real-World Data for Eversense 365
SENS highlights strong one-year real-world data for Eversense 365, reinforcing adherence, glucose control and long-term adoption potential.